Clearmind Medicine Partners with Polyrizon to Develop Intranasal Formulation for MEAI Compound.
ByAinvest
Friday, Feb 6, 2026 7:56 am ET1min read
CMND--
PLRZ--
Clearmind Medicine has partnered with Polyrizon to develop an intranasal formulation for its lead compound, MEAI, which is designed to treat addiction-related disorders and CNS conditions. The collaboration aims to enhance bioavailability and support clinical advancement of MEAI by leveraging Polyrizon's proprietary intranasal hydrogel technology. This could improve the drug's efficacy, duration of effect, and patient usability. The intranasal delivery method offers advantages over traditional oral routes, including faster absorption and lower effective dosing.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet